Transcriptomic and proteomic approaches reveal biological basis of intraoperative radiotherapy-treated tumor bed modification in breast cancer patients: A pilot study.


Journal

Journal of proteomics
ISSN: 1876-7737
Titre abrégé: J Proteomics
Pays: Netherlands
ID NLM: 101475056

Informations de publication

Date de publication:
10 02 2020
Historique:
received: 11 08 2019
revised: 03 11 2019
accepted: 19 11 2019
pubmed: 24 11 2019
medline: 15 4 2021
entrez: 24 11 2019
Statut: ppublish

Résumé

Intraoperative electron Radiotherapy, herein referred to, as IOeRT is a novel approach in breast cancer (BC) treatment. This study designed to investigate short-term molecular effects of 12Gy as Boost versus 21Gy as Radical dose of IOeRT using high throughput approaches. Six BC patients as a pilot study were treated with IOeRT following two separate strategies, including Boost and Radical doses. Approximately 100 mg of tumor bed tissue retrieved from each patient (before IOeRT,immediately, 24 h post-treatment). mRNA sequencing also Isobaric tag for relative and absolute quantitation (iTRAQ) were performed to study the transcriptome and proteome profile of IOeRT-treated tumor bed. Using NGS, ~6 Giga base (GB) clean data per individual samples were generated. Moreover, by iTRAQ for proteome quantification, in total, 1,045,410 spectrums were generated, likewise 5860 proteins were identified (FDR <0.01). Functional annotation and gene ontology (GO) indicated that significant enrichment in molecular pathways on BC treatment is somehow single high dose-independent. This means that, key molecular pathways in radiotherapy (RT) are equally enriched by both Boost and Radical doses. Generally, by modification of the Radical dose, with the same effectiveness, it is possible to reduce single high dose irradiation in BC.

Identifiants

pubmed: 31759177
pii: S1874-3919(19)30368-9
doi: 10.1016/j.jprot.2019.103596
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Proteome 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103596

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Minoo Shahani (M)

Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Jafar Shakeri (J)

Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mohammad Esmaeil Akbari (ME)

Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: crc@sbmu.ac.ir.

Babak Arefnezhad (B)

OMICS Research Group (Media Teb Gene), Tehran, Iran.

Ali Tafti (A)

Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Departeman of Medical Biotechnology, Faculty of Medicine, Arak University of Medical Science, Arak, Iran.

Hakimeh Zali (H)

School of Advanced Technology in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Nahid Nafisi (N)

Breast Department, Iran University of Medical Sciences, Tehran, Iran.

Mehrdad Hashemi (M)

Department of Genetics, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran.

Mostafa Rezaei-Tavirani (M)

Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Somayeh Mohammadpour (S)

Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Seyyed Ali Reza Salami (SAR)

Department of Biotechnology, University of Tehran, Iran.

Hamid Reza Mirzai (HR)

Cancer Research Center, Shohadae Tajrish Hospital, Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Majid Samsami (M)

Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Seyed Hamid Jamaldini Ezabady (SHJ)

Department of Genetics, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran.

Atieh Akbari (A)

Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH